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Abstract
Purpose Intravenous solutions are often administered to
the mother on the day of a cesarean delivery to minimize
the effect of preoperative fasting or to stabilize the
hemodynamics. Different intravenous solutions contain
varying amounts of glucose, and rapid administration may
lead to hypoglycemia in the neonate. We conducted a study
to compare blood glucose levels of the mother and the
fetus/neonate after they were rapidly given a Ringer’s
solution containing 0, 1, or 5 % glucose. The effect of the
glucose load that these intravenous solutions impose during
cesarean delivery has not been fully reported. Therefore,
we compared the effect of 0 % (Group I, n = 15), 1 %
(Group II, n = 15), and 5 % (Group III, n = 15) glucose
acetated Ringer’s solutions on maternal and umbilical
blood glucose levels to determine the optimal glucose
concentration.
Methods Once the patients were in the operating room,
the intravenous solutions were administered before deliv-
ery. The primary endpoint was changes in umbilical blood
glucose levels and minimum neonatal blood glucose levels,
and the secondary endpoint was the proportion of neonates
who received a glucose infusion.
Results Maternal blood glucose levels before and after
intravenous infusion were 79.2 ± 12.2 and 74.6 ± 4.6 in
Group I, 81.2 ± 12.9 and 103.3 ± 11.2 in Group II
(P \ 0.001), and 82.3 ± 8.7 and 252.5 ± 41.8 in Group III
(P \ 0.001). Umbilical blood glucose levels were 53.9 ±
10.2 in Group I, 80.8 ± 13.7 in Group II, and 181.8 ± 22.2
in Group III (P \ 0.01: Group I vs. Group II and P \ 0.01:
Group II vs. Group III) (P \ 0.001: Group I vs. Group III).
Minimum neonatal blood glucose levels measured up to
8 h after birth were 35.7 ± 9.6 in Group I, 49.8 ± 10.8 in
Group II, and 29.2 ± 7.5 in Group III. Neonatal hypogly-
cemia requiring glucose before the first milk feeding
occurred in 6 neonates whose mothers were in Group I, 3 in
Group II, and 9 in Group III, indicating a trend towards less
neonatal hypoglycemia in Group II.
Conclusions The use of 1 % glucose acetated Ringer’s
solution did not induce hyperglycemia in the mother and it
was able to maintain appropriate blood glucose levels in
the fetus.
Keywords 1 % glucose acetated Ringer’s solution 
Blood glucose  Perioperative infusion
Introduction
Intravenous glucose solutions may be given to patients who
undergo cesarean deliveries to provide the mother and fetus
with energy, and glucose-free crystalloid solutions are
given to maintain hemodynamics. However, glucose load
from preoperative intravenous solutions may result in
hyperglycemia or hypoglycemia in the fetus.
Anesthesia induction often causes an abrupt change in
hemodynamics, and such change, especially a decrease in
blood pressure, harms both mother and fetus. To reverse the
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change, a vasopressor is promptly administered, and rapid
intravenous infusion is often performed to have a faster effect.
However, depending upon the intravenous solutions used,
rapid administration may result in maternal and fetal hyper-
glycemia, which eventually could lead to reflex hypoglycemia
in the neonate [1]. The optimal glucose concentration for
intravenous solutions that would be effective for maintaining a
safe range of blood glucose both in mothers and fetuses has not
been established. Normally, mothers with blood glucose lev-
els of 40 mg/dL or lower and fetuses with levels of 30 mg/dL
or lower are diagnosed as having hypoglycemia [2]. A
neurophysiological study indicates that developmental dis-
orders will occur if the neonate’s blood glucose level becomes
2.6 mmol/L (equivalent to 48 mg/dL) or lower, which is
consistent with the diagnostic criterion previously mentioned
[3]. Intravenous solutions of acetated Ringer’s used during
surgery can be generally categorized based on glucose load
into the following 3 types: 0 % acetated Ringer’s solution (no
glucose, 500 mL), 1 % acetated Ringer’s solution (5 g glu-
cose, 500 mL), and 5 % acetated Ringer’s solution (25 g
glucose, 500 mL) (Table 1). The effect of the glucose load
that these intravenous solutions impose during cesarean
delivery has not been fully reported. Therefore, we compared
the effect of 0, 1, and 5 % glucose acetated Ringer’s solu-
tions on maternal and umbilical blood glucose levels to
determine the optimal glucose concentration.
Patients and methods
The study was approved by the Institutional Ethics Com-
mittee of the National Defense Medical College. The
patients were fully informed about the study, and written
informed consent was obtained. Forty-five pregnant
women scheduled for elective cesarean delivery were
included. Patients with gestational diabetes or pregesta-
tional diabetes or those receiving intravenous solutions
with glucose due to preoperative complications, such as
threatened premature labor, were excluded.
The 45 patients were randomly assigned to 3 groups:
0 % glucose acetated Ringer’s solution (Group I), 1 %
glucose acetated Ringer’s solution (Group II), and 5 %
glucose acetated Ringer’s solution (Group III). All patients
received an infusion of 0 % glucose acetated Ringer’s
solution (1000–1500 mL) via the forearm the day before
their surgery was scheduled; preoperative fasting started at
21:00 the night before the scheduled cesarean delivery
section. Patients were not given any other medications,
including anesthetics, before their scheduled delivery
(Fig. 1).
Lumbar epidural anesthesia was performed by injecting
15 mL of 1 % ropivacaine via the L3-4 interspace. A Teflon
needle was placed in the radial artery to monitor arterial
pressure and to take maternal blood samples. Each group
received 500 mL of the test solution, and administration was
completed before delivery. As for glucose load; Group I
received 0 g glucose; Group II, 5 g glucose; and Group III,
25 g. To determine glucose levels, maternal blood samples
were obtained before intravenous infusion and immediately
after delivery; umbilical blood was obtained immediately
after delivery to measure glucose levels and pH. The neo-
nate’s body weight was also measured and the Apgar score
determined by a neonatologist. Neonates with a minimum
blood glucose level of 50 mg/dL or lower within 8 h of
delivery were given a glucose infusion.
Results were expressed as mean ± SD and median
(minimum–maximum). One-way analysis of variance
(two-sided at a = 0.05) and Chi-squared test were per-
formed for statistical analyses by using Prism 5 for Mac
OS X (1992–2008, GraphPad Software, Inc.). If one-way
ANOVA gave a P value less than 0.05, a post hoc test
(Dunnett’ method) was performed. Differences in the
patient’s demographic characteristics were considered
significant at the 0.15 level.
Results
Cesarean deliveries were performed in patients with breech
presentation (22.2 %), repeated cesarean section (CS)
(40.0 %), maternal request (0.04 %), and after myomectory
CS (33.3 %).
Table 1 Composition of test solutions
Name Group
name






0 % Glucose acetated
Ringer’s solution
Group I 130 4 3 – 109 – – 28 – Approx. 1
1 % Glucose acetated
Ringer’s solution
Group II 140 4 3 2 115 3 6 25 1 Approx. 1
5 % Glucose acetated
Ringer’s solution
Group III 130 4 3 – 109 – – 28 5 Approx. 2
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For the mothers, there were statistically significant dif-
ferences in age, gestational week, and anesthesia time;
whereas there were no differences in height, body weight,
or amount of bleeding or oxytocin received (Table 2). For
the neonates, there were no differences in body weight or
Apgar scores (Table 3). Before and after the start of the
intravenous infusion, the maternal blood glucose levels
(mg/dL) were 79.2 ± 12.2 and 74.6 ± 4.6 in Group I,
81.2 ± 12.9 and 103.3 ± 11.2 in Group II, and 82.3 ± 8.7
and 252.5 ± 41.8 in Group III (Table 4). Group II and
Group III showed significant differences in blood glucose
levels before and after the start of the intravenous infusion
(Group II, P \ 0.001; Group III, P \ 0.001), and between-
group differences were noted; significant differences between
the 3 groups were also found (Group I vs. Group II,
P \ 0.001; Group II vs. Group III, P \ 0.001; Group I vs.
Group III, P \ 0.001; one-way ANOVA, P \ 0.05).
Immediately after delivery, umbilical blood glucose levels
(mg/dL) were 53.9 ± 10.2 in Group I, 80.8 ± 13.7 in
Group II, and 181.8 ± 22.2 in Group III (Table 5). Of the 3
groups, Group III had the highest blood glucose levels, and
there were significant differences between the 3 groups
(Group I vs. Group II, P \ 0.01; Group II vs. Group III,
P \ 0.01; Group I vs. Group III, P \ 0.001; one-way
ANOVA, P \ 0.05). The minimum neonatal blood glucose
levels within 8 h after birth (mg/dL) were 35.7 ± 9.6 in
Group I, 49.8 ± 10.8 in Group II, and 29.2 ± 7.5 in Group
III (Table 5). Group I and Group III showed significantly
lower minimum blood glucose levels within 8 h after
birth than in Group II (Group I vs. Group II, P \ 0.05;
Group II vs. Group III, P \ 0.01).
Based on the reference range of our institution, a neo-
nate with a minimum blood glucose level of 50 mg/dL
(2.8 mmol/L) or lower measured within 8 h after birth was
diagnosed as having neonatal hypoglycemia and given
treatment with a glucose infusion. In this study, 6 neonates
in Group I, 3 in Group II, and 9 in Group III received a
glucose infusion before the first milk feeding; neonates in
Group II showed a trend towards a less frequent glucose
infusion (P = 0.082) (Table 6).
Discussion
In our study, we compared maternal, umbilical, and neo-
natal (8 h after birth) blood glucose levels to investigate the
optimal glucose infusion in neonates. Baseline maternal
characteristics showed statistically significant differences
in age, gestational week, and anesthesia time in 3 groups;
however, they were not considered clinically important. As
a result, those who received 1 % glucose (Group II) had
significantly lower glucose levels than other groups. There
were significant differences in umbilical blood glucose and
minimum neonatal blood glucose levels within 8 h after
birth between groups receiving Ringer’s solutions with
different glucose concentrations (0, 1, and 5 %).
Generally, cesarean deliveries are performed under local
anesthesia such as epidural or spinal anesthesia. However,
local anesthesia often results in a decrease in blood pressure
because of sympathetic nervous blockade, which should be
promptly reversed because such hypotension will harm not
only the mother but also the fetus. To stabilize the blood
Fig. 1 Time schedule of the
study
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pressure, a vasopressor is generally administered, and rapid
infusion of an intravenous solution is often concomitantly
used to have a faster effect. Currently, several solutions with
different glucose concentrations are available for cesarean
delivery, but are characterized by no uniformity.
Glucose passes between the mother and fetus through
the placenta by diffusion, but its correlation coefficient is
high, and there is no limit to the amount of glucose that can
be passed [4]. Normally, the difference in blood glucose
levels between the mother and fetus is within 20 mg/dL,
but if the mother receives a rapid glucose-containing
infusion, the umbilical glucose levels have been reported to
increase to 300 mg/dL or more [5].
Table 2 Baseline maternal characteristics
0 % Glucose acetated Ringer’s
solution Group I (n = 15)
1 % Glucose acetated Ringer’s
solution Group II (n = 15)
5 % Glucose acetated Ringer’s
solution Group III (n = 15)
P
Age (year) 34.5 ± 2.6 33.5 ± 3.6 31.9 ± 4.1 0.14
Height (cm) 158.4 ± 4.2 158.0 ± 4.9 157.0 ± 6.3 0.75
Body weight (kg) 62.6 ± 6.6 61.7 ± 6.5 61.1 ± 6.0 0.79
Gestational week 36.9 ± 1.7 37.4 ± 2.7 36.1 ± 1.7 0.13
Amount of
oxytocin used (U)
23.3 ± 6.7 22.7 ± 14.5 21.0 ± 6.7 0.80
Blood loss (g) 1110 ± 457.4 912.7 ± 354.7 895.7 ± 378.9 0.84
Anesthetic time
(min)
117.6 ± 35.2 115.3 ± 41.6 111.1 ± 40.8 0.07
Mean ± SD
One-way ANOVA, a = 0.15
Table 3 Baseline neonatal characteristics
0 % Glucose acetated Ringer’s
solution Group I (n = 15)
1 % Glucose acetated Ringer’s
solution Group II (n = 15)
5 % Glucose acetated Ringer’s




2668.0 ± 460.3 2685 ± 593.1 2570.0 ± 566.6 0.53
Apgar score
1 minb
9 (8–9) 9 (7–9) 9 (8–9) 0.53
Apgar score
5 minb
10 (9–10) 10 (9–10) 10 (9–10) 0.72
Fetal pHb 7.428 (7.389–7.466) 7.391 (7.310–7.452) 7.386 (7.327–7.431) 0.36
One-way ANOVA, a = 0.15
a Mean ± SD
b Mean (minimun–maximum)
Table 4 Blood glucose levels of mothers
One-way ANOVA, a = 0.05
Mean ± SD
*** P \ 0.001 for pre-infusion versus post-infusion
fff P \ 0.001 for each groups
Table 5 Blood glucose levels of fetuses and neonates
One-way ANOVA, a = 0.05
Mean ± SD
NS not significant
f P \ 0.05 for each groups
ff P \ 0.01for each groups
fff P \ 0.001 for each groups
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The use of glucose infusion in cesarean delivery has not
been established.
Carbohydrate metabolism plays a central role in fetal
metabolism. In 1959, Dawes and others [5] described the
positive correlation between the period that a fetus can
survive with anoxia and the amount of glycogen that
accumulates in the heart [6]. During delivery, energy is
derived from glucose via the Emden–Meyerhof pathway.
When the mother–fetal condition is normal, increased fetal
blood glucose is not as problematic as in instances of fetal
distress, when providing glucose has been reported to
benefit the fetus [7, 8]. If the fetus is stressed, catechola-
mines secreted from the adrenal gland and nerve endings
enhance key enzymes of the Emden–Meyerhof pathway,
degrade glycogen, and increase the blood glucose level.
Furthermore, glucose load from intravenous solutions
results in fetal hyperglycemia, and the excess glucose is not
metabolized in the Krebs cycle, which may increase blood
lactic acid and ultimately lead to lactic acidosis [1].
Especially rapid and large-dose administration should be
contraindicated in cesarean delivery because it can result in
maternal and fetal hyperglycemia, which may eventually
lead to reflex hypoglycemia in the neonate [9–11].
In Japan, hypoglycemia in infants is generally defined as a
blood glucose level of 30 mg/dL (1.7 mmol/L) or lower.
However, as mentioned above, at our institution, for safety,
the definition of hypoglycemia in neonates is a minimum
blood glucose level of 50 mg/dL (2.8 mmol/L) or lower
within 24 h after delivery [2]. Deshpande and colleagues [3]
have reported that a blood glucose level of 48 mg/dL
(2.6 mmol/L) or lower in neonates may lead to developmental
disorders. Another study recommends that neonates with any
abnormal clinical signs should be treated to have a blood
glucose level of 45 mg/dL (2.5 mmol/L) or higher [12].
As for blood glucose levels of the neonate after birth,
Marom and colleagues showed that neonates had a level of
70.9 ± 9.7 mg/dL when preoperative fasting lasted at least
6 h for mothers scheduled to have a cesarean delivery [13].
On the other hand, hypoglycemia may occur because
pregnant women who are scheduled for elective cesarean
delivery are required to fast after 21:00 the night before
surgery. If the neonate’s minimum blood glucose level is
50 mg/dL or lower within 8 h of birth, parenteral nutrition
with a glucose-containing solution is begun to ensure the
neonate’s safety. In our study, neonates in Groups I and III
were more likely to receive therapy than neonates in Group
II. As a result, blood glucose levels in neonates in those 2
groups were significantly higher (Table 3). Group I moth-
ers had hypoglycemia (no glucose load), which led to
hypoglycemia in the neonate. In contrast, neonates in
Group III had hyperglycemia immediately after birth. The
glucose load in Group III mothers led to hyperglycemia
and, subsequently, hyperinsulinemia in the fetus. In ter-
minal gestation, mean immunoreactive plasma insulin (IRI)
is 5 lU/mL, which increases along with the elevation in
fetal blood glucose levels due to maternal glucose load and
fetal stress: there is a positive correlation between fetal
blood glucose and fetal plasma insulin [14–16]. When the
umbilical cord is clamped at delivery, however, glucose
supply is terminated abruptly, leading to severe hypogly-
cemia due to hyperinsulinemia.
As a limitation of our study, we did not measure
maternal, fetal, or neonatal insulin levels directly, which
needs to be further investigated in future studies. In our
hospital, glucose infusion is given as a prevention of neo-
natal hypoglycemia, but clinically speaking, first milk
feeding may be started earlier. Also, this study was con-
ducted as an exploratory study, and the sample size was not
calculated, which might have led to the inconclusive results
regarding glucose infusion in neonates with no statistical
difference due to lack of statistical power. Further clinical
studies with appropriate sample sizes may be conducted in
the future.
The true purpose of our study is to further investigate
how patients with gestational diabetes or pregestational
diabetes respond to intravenous glucose solution. As a next
step, we are planning to conduct a study with patients with
pregestational diabetes.
In conclusion, our study results suggest that adminis-
tration of 1 % glucose acetated Ringer’s solution (500 mL)
during cesarean delivery is a reasonable treatment to
maintain appropriate glucose levels in neonates.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Table 6 Number of neonates
who received treatment





1 % Glucose acetated
Ringer’s solution
Group II (n = 15)
5 % Glucose acetated
Ringer’s solution
Group III (n = 15)
P




6 3 9 0.082
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